Article

Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor miRNAs

2023-06-05

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Fibroblast growth factor receptor (FGFR) gene family alterations are found in several cancers, indicating their importance as potential therapeutic targets. The FGFR-tyrosine kinase inhibitor (TKI) pemigatinib (Pemazyre<sup>®</sup>, INCB054828) has been introduced in the treatment plan for advanced cholangiocarcinoma and more recently for relapsed or refractory...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: aa4bdf85-4142-5515-b1d4-1d8ef3fe5a58
DOI: 10.21203/rs.3.rs-2979694/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor miRNAsDOI 10.21203/rs.3.rs-2979694/v1Read

Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.Semantic proximity Read

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.Semantic proximity Read

miR-325-3p Facilitates Tumorigenesis and Acquired Pemigatinib Resistance in Intrahepatic Cholangiocarcinoma via Targeting ADH1B through Epithelial–Mesenchymal Transition and PI3K/AKT SignalingSemantic proximity Read

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.Semantic proximity Read

The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.Semantic proximity Read

RAS/RAF/MEK Inhibitors in OncologySemantic proximity Read

Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumorsSemantic proximity Read

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 RearrangementSemantic proximity Read

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.Semantic proximity Read

Molecular Targeting of the Fibroblast Growth Factor Receptor (FGFR) Pathway Across Various CancersSemantic proximity Read

PTPN9 dephosphorylates FGFR2pY656/657 through interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinomaSemantic proximity Read

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Semantic proximity Read